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Abstract
Introduction Preterm birth accounts for more than
85% of all perinatal complications and deaths. Seventyfive per cent of early preterm births (EPTBs) occur
spontaneously and without identifiable risk factors.
The need for a broadly applicable, effective strategy
for primary prevention is paramount. Secondary
outcomes from the docosahexaenoic acid (DHA) to
Optimise Mother Infant Outcome trial showed that
maternal supplementation until delivery with omega-3
(ω-3) long chain polyunsaturated fatty acid (LCPUFA),
predominantly as DHA, resulted in a 50% reduction in
the incidence of EPTB and an increase in the incidence
of post-term induction or post-term prelabour caesarean
section due to extended gestation. We aim to determine
the effectiveness of supplementing the maternal diet
with ω-3 LCPUFA until 34 weeks’ gestation on the
incidence of EPTB.
Methods and analysis This is a multicentre, parallel
group, randomised, blinded and controlled trial. Women
less than 20 weeks’ gestation with a singleton or multiple
pregnancy and able to give informed consent are eligible
to participate. Women will be randomised to receive
high DHA fish oil capsules or control capsules without
DHA. Capsules will be taken from enrolment until 34
weeks’ gestation. The primary outcome is the incidence
of EPTB, defined as delivery before 34 completed weeks’
gestation. Key secondary outcomes include length of
gestation, incidence of post-term induction or prelabour
caesarean section and spontaneous EPTB. The target
sample size is 5540 women (2770 per group), which will
provide 85% power to detect an absolute reduction in
the incidence of preterm birth of 1.16% (from 2.45% to
1.29%) between the DHA and control group (two sided
α=0.05). The primary analysis will be based on the
intention-to-treat principle.
Trial registration number Australia and New Zealand
Clinical Trial Registry Number: 2613001142729; Preresults.

Introduction
Background
Preterm birth, or birth before 37 completed
weeks of pregnancy, is the leading cause of

Strengths and limitations of this study
►► This study is the largest randomised controlled trial

with adequate power that is designed to assess the
effect of omega-3 (ω-3) long chain polyunsaturated
fatty acid (LCPUFA) supplementation in pregnancy
on the incidence of early preterm birth (EPTB) as the
primary outcome.
►► The study uses an innovative intervention strategy,
which is unique compared with other trials in this
field. The intervention targets the period before and
during the time when EPTB is likely to occur and it is
ceased at 34 weeks’ gestation, at which time EPTB
has been prevented. This strategy may reduce the
risk of post-term birth.
►► The study assesses maternal LCPUFA status at
baseline and at the end of the intervention period,
providing an independent biomarker of compliance,
in addition to maternal self-report and capsule back
count.
►► The study is conducted in an industrialised setting
where intake of ω-3 LCPUFA is low. Findings from
this study may not be applicable in populations with
high intake of ω-3 LCPUFA.

death in newborns, accounting for more
than 85% of all perinatal complications and
death.1 It is estimated that 10% of births
(13 million babies each year worldwide) are
preterm and 20% of these preterm births
occur before 34 weeks, these being referred
to as early preterm birth (EPTB). It is EPTB
that is the major cause of perinatal mortality,
serious neonatal morbidity and moderate
to severe childhood disability in developed
countries.2–4 Effective, broadly applicable
primary prevention strategies to reduce the
risk of EPTB are lacking.
Prostaglandins and other lipid mediators
derived from omega-6 (ω-6) and omega-3
(ω-3) fatty acids play essential roles in normal
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supplementation during the last half of pregnancy on
the prevalence of postnatal depression in women and
on early childhood neurodevelopmental outcomes. We
enrolled 2399 women from five perinatal centres around
Australia who were randomly assigned to receive identical
looking capsules containing either fish oil concentrate
(900 mg ω-3 LCPUFA/day) or a blend of vegetable oils
(no ω-3 LCPUFA) from 20 weeks’ gestation until birth. In
a prespecified secondary analysis, there were fewer EPTB
in the ω-3 LCPUFA supplemented group compared
with control (1.09% vs 2.25%, adjusted RR 0.49, 95% CI
0.25 to 0.94, p=0.03) and fewer admissions to level three
intensive care (1.75% vs 3.08%, RR 0.57, 95% CI 0.34 to
0.97, p=0.04). Similar findings were reported in a smaller
US trial (n=301), the Kansas University DHA Outcomes
(KUDOS) Study,17 which showed that supplementation
with 600 mg of DHA daily from mid-pregnancy until birth
resulted in a reduction in the incidence of EPTB (0.6%
vs 4.8%, p=0.025). The effect of DHA supplementation
in pregnancy in lowering the risk of EPTB observed
in both the DOMInO and KUDOS trials is consistent
with the Cochrane review18 published before these two
trials. Despite these encouraging findings, results have
been viewed with caution by researchers and clinicians
because EPTB was a secondary outcome of the DOMInO
and KUDOS trials. A recent update to this Cochrane
review (publication pending) includes 54 randomised
trials with a total of >15 000 participants. Results show a
clear reduction in EPTB (RR 0.61, 95% CI 0.46 to 0.81; 9
randomised controlled trials (RCTs); n=4351) for supplementation compared with placebo.19 Our DOMInO trial
supports the safety data from previous systematic reviews;
however, there were more post-term births requiring
obstetric intervention (induction or caesarean section)
in the ω-3 LCPUFA supplemented group compared with
control (17.59% vs 13.72%, adjusted RR 1.28, 95% CI 1.06
to 1.54, p=0.01). To determine both efficacy and safety
of this intervention, we therefore plan to undertake a
further trial with adequate power to assess the effect of
ω-3 LCPUFA supplementation in pregnancy on EPTB as
the primary outcome, with a unique design ceasing the
intervention at 34 weeks’ gestation to reduce the risk of
post-term birth.
Hypotheses
Optimising ω-3 LCPUFA intake in pregnancy will lead to
lower risk of EPTB.
Methods
Trial design
The ORIP trial is designed as a randomised, controlled,
clinician, researcher and participant/family blinded,
multicentre trial with two parallel groups and a primary
outcome of incidence of EPTB, defined as delivery before
34 completed weeks’ gestation.
Participating centres
The sponsoring institution and Trial Coordinating Centre
is the South Australian Health and Medical Research
Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360
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and pathologic initiation of labour.5 6 The fetoplacental
unit is supplied with long chain polyunsaturated fatty
acids (LCPUFA) from the maternal circulation, which is
influenced by maternal LCPUFA intake and endogenous
synthesis. Prostaglandins derived from ω-6 arachidonic
acid are countered by those derived from ω-3 LCPUFA
within the same tissues. The balance between the metabolites of ω-3 and ω-6 fatty acids plays an important role
in the maintenance of normal gestation length and is a
critical element in cervical ripening and the initiation of
labour.7 If local production of ω-6 derived prostaglandins
within the fetoplacental unit is too high, or local accumulation of ω-3 LCPUFA is too low, the cervix may prematurely ripen and uterine contractions increase, which may
in turn lead to preterm birth or EPTB.
Current Western diets are low in ω-3 LCPUFA.8 The
Suppl 20 WHO recommends an intake of 300 mg/day of
ω-3 LCPUFA for pregnant women; however, the median
intake in Australian women of childbearing age is only
29 mg/day9 compared with 1000 mg/day in women
from nations with high-fish consumption such as Japan,
Korea and Norway. The intake of ω-3 LCPUFA is further
reduced among pregnant women due to a reduced
intake of all fish following advisories for pregnant women
to avoid specific long-lived predatory fish due to the
concern about mercury contamination.10 The level of ω-3
LCPUFA intake estimated to achieve normal rises in the
fetoplacental unit for the maintenance of a full-term pregnancy is well above the intake of many pregnant women,
highlighting a potential insufficiency for the uterus and
fetoplacental unit. Optimising ω-3 LCPUFA intake in
pregnancy may restore the balance between ω-3 and ω-6
fatty acids and reduce the risk of preterm birth.
At the time the trial started, only two of the six included
trials in the Cochrane review11 of marine oil supplementation in pregnancy reported the effect on EPTB.
Both trials12 13 were conducted in high-risk pregnancies
designed to assess the effect of ω-3 LCPUFA supplementation to prevent reoccurrence of intrauterine growth
restriction, preterm birth or pregnancy induced hypertension. From these two relatively small trials (total of
860 women), it was seen that women allocated to receive
fish oil had a lower risk of EPTB compared with control
(relative risk (RR) 0.69, 95% CI 0.49 to 0.99). Systematic
reviews11 14 15 have shown no difference in the incidence of
antepartum hospitalisation, caesarean section, eclampsia
or other serious maternal morbidity between treatment
(ω-3 LCPUFA supplements) and control groups. The RR
of miscarriage, stillbirth and neonatal death also did not
differ between the groups.11 14 15 None of the included
trials reported the effect of ω-3 LCPUFA supplementation
on EPTB in the general population of pregnant women.
The strongest evidence to support the efficacy of ω-3
LCPUFA supplementation to reduce EPTB comes from
our docosahexaenoic acid (DHA) to Optimise Mother
Infant Outcome (DOMInO) trial,16 the largest trial to
date of ω-3 LCPUFA supplementation in pregnancy.
DOMInO was designed to assess the effect of ω-3 LCPUFA
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Study population
Participants are pregnant women less than 20 weeks’
gestation.
Eligibility criteria
Pregnant women are approached by trained clinical trial
personnel in the antenatal clinic of participating centres.
Inclusion criteria
Women must meet both the following criteria to be
enrolled in this study:
►► Singleton or multiple pregnancy and less than 20
weeks’ gestation.
►► Able to give informed consent.
Exclusion criteria
Women must not have any of the following criteria to be
enrolled in this study:
►► Fetus with a known abnormality.
►► Taking dietary supplements containing LCPUFA
>150 mg/day.
►► Taking dietary supplements containing LCPUFA
<150 mg/day and are not willing to stop.
►► Bleeding disorders where fish oil is contraindicated or
on anticoagulant therapy.
►► History of drug or alcohol abuse.
Study treatments
Participating women will be randomised to high-DHA fish
oil capsules or vegetable oil capsules. The study capsules
are identical in colour, size, shape and packaging and
are iso-caloric. Women will be asked to consume three
capsules per day.
DHA capsules
Each 500 mg DHA enriched fish oil capsule contains
approximately 300 mg of ω-3 LCPUFA. Women will be
asked to take three capsules per day orally, which will
provide approximately 1 g of ω-3 LCPUFA (800 mg of
DHA and 100 mg of eicosapentaenoic acid per day. The
remaining portion of oil consists of monounsaturated
and saturated fatty acids.
Control capsules
The control capsules (also 500 mg in weight) contain a
blend of vegetable oils (canola, sunflower and palm oils)
with a trace of tuna oil (12.6 mg ω-3 LCPUFA) to assist
with blinding. This blend of oil matches the fatty acid
composition of the typical Australian diet.
Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360

Manufacture of study capsules
The active and control capsules are manufactured in a
licensed facility (licensed according to the Code of Good
Manufacturing Practice (GMP)) and have been donated
to the trial by Efamol Ltd/Wassen International Ltd. The
capsules are packaged and labelled in accordance with
GMP including an individual product identifier (ID),
batch number, expiry date and the statement ‘for clinical trial use only’. The pharmacist or the investigator’s
designee maintains accurate records of the receipt of all
study capsules, including dates of receipt. Unused study
capsules will be destroyed in compliance with applicable
regulations.
Monitoring adherence to study treatment
Research personnel in each centre will maintain regular
contact with participating women to monitor and
encourage capsule adherence and study compliance and
answer any questions as they arise. Women are asked to
return unused capsules at the final study visit (34 weeks’
gestation) and the proportion of capsules returned serves
as an additional measure of compliance. A finger prick
blood specimen collected from the woman at this final
visit will be used in fatty acid analysis as an independent
biomarker of adherence. All clinical care for women
involved in this trial will be undertaken by her designated
obstetric/midwifery care provider.
Outcome measures
The primary outcome of this trial is the incidence of EPTB,
defined as delivery before 34 completed weeks’ gestation.
Gestational age (GA) in days at delivery for primary and
secondary outcomes will be determined from the estimated date of delivery (EDD) using the equation (280
– (EDD – date of birth)). EDD will be determined using
a combination of maternal menstrual dating and ultrasound dating in accordance with established obstetric
practice, as outlined in figure 1.
Key secondary outcomes
Length of gestation
Post-term induction or post-term prelabour caesarean
section
►► Preterm birth (<37 completed weeks)
►► Spontaneous EPTB
►► Birth weight
►► Low birth weight (<2500 g)
►► Admission to Neonatal Intensive Care Unit
►► Perinatal death (stillbirth and death within first 28
days of birth)
►►
►►

Other outcomes
Spontaneous preterm birth, prelabour rupture
of membranes, prelabour, preterm rupture of
membranes.
►► Birth length, birth head circumference, small for GA,
very small for GA, large for GA, very large for GA.
►► The length of hospital stay of infants and mothers,
length of admission in Neonatal Intensive Care Unit.
►►
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Institute based at the Women’s and Children’s Hospital,
Adelaide, South Australia. The trial is being conducted
in the following six centres in Australia: Women’s &
Children’s Hospital, Flinders Medical Centre and Lyell
McEwin Hospital in South Australia; Joondalup Health
Campus, Western Australia; Werribee Mercy Hospital,
Werribee, Victoria and Mater Mothers Hospital, Brisbane,
Queensland.
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►►

►►

4

Pregnancy and labour outcomes including gestational diabetes, pregnancy-induced hypertension,
pre-eclampsia, eclampsia, maternal use of antibiotics,
caesarean section, estimated blood loss at birth and
postpartum haemorrhage.
Incidence of serious adverse event (SAE) defined as
maternal, neonatal or fetal deaths (stillbirth); fetal loss
(miscarriage); maternal admissions to intensive care;
admissions to intensive care for infants born after 34
weeks’ gestation and major congenital anomalies.
Neonatal complications including jaundice (requiring
phototherapy), hypoglycaemia (requiring intravenous

►►

dextrose infusion), neonatal convulsion, brain injury
(including intraventricular haemorrhage), retinopathy of prematurity, sepsis, necrotising enterocolitis
and duration of supplemental oxygen. The definitions and classifications of these neonatal complications are in accordance with the Australian and New
Zealand Neonatal Network Data Dictionary.20
Other side effects and tolerability of DHA supplementation assessed through data collected in the case
report form (CRF).

Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360
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Figure 1 Flow chart for determining EDD. EDD, estimated date of delivery; GA, gestational age; LMP, last menstrual period;
U/S ultrasound; w, weeks.

Open Access
Six weeks following delivery, research personnel will
extract details of pregnancy, labour and birth from the
woman and her baby’s medical records for primary and
secondary outcome data; see figure 2 for a summary of
the ORIP trial schema.
Sample size
Our previous trial of DHA supplementation of pregnant women, the DOMInO trial,16 included women
with singleton pregnancies and treatment resulted in a
1.16% absolute reduction (from 2.25% to 1.09%) in the
incidence of EPTB. This reduction occurred in the presence of non-adherence resulting from women assigned
to the intervention failing to take the trial supplements
as directed, and control women taking prenatal supplements containing low dose ω-3 LCPUFA. Similar levels of

Figure 2 ORIP trial schedule. **–t1=<20 weeks’ gestation; t1=2 weeks’ post-randomisation and allocation; t2=28 weeks’
gestation; t3=34 weeks’ gestation or birth, whichever occurs first; tx=6 weeks post-estimated due date. ω-3 LCPUFA, omega-3
long chain polyunsaturated fatty acid.
Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360
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Participant timeline
Women will be randomised and commence study treatment capsules from enrolment (<20 weeks’ gestation)
until 34 weeks’ gestation or birth, whichever occurs first.
At enrolment, following informed consent and prior to
commencement of study treatment, research personnel
will collect a finger prick blood sample for baseline
fatty acid status. The woman’s height and weight will be
measured and baseline clinical and demographic data
collected. Research personnel will contact the participant
2 weeks following the enrolment visit and again when the
woman is 28 weeks’ gestation to ascertain capsule adherence and record adverse events. At 34 weeks’ gestation,
participating women will attend a clinic appointment for
collection of a finger prick blood sample for fatty acid
analysis and unused capsules are returned and counted.

Open Access

Recruitment
Women will be approached to enter the trial by research
staff at the time of attending their routine antenatal visit
at one of the centres involved. Pregnant women will
also be informed about the trial by display of approved
advertising material which will be circulated in hard copy
and via social media avenues. A participant information
sheet describing the purpose of the study, the procedures
to be followed and the risks and benefits of participation will be explained to interested women. Following
a screening process to ensure inclusion and exclusion
criteria are met, the investigator or nominee will conduct
the informed consent discussion and will check that
information provided is understood and answer any questions about the study. A record of all women screened and
their enrolment status will be maintained to adhere to the
consolidated standards for the reporting of randomised
controlled trials.21 Women may withdraw their involvement in the trial at any time and, wherever possible, the
reason for withdrawal will be recorded.
Randomisation procedures
Once the consent process has been documented by
signing of the written consent form, the participant will
be randomised using a web-based randomisation service.
Stratification will be by centre and current supplement
use (no LCPUFA vs ≤150 mg LCPUFA/day prior to
randomisation). Allocation follows a computer-generated
randomisation schedule with balanced variable blocks,
prepared using ralloc.ado V.3.7.5 in Stata V.12.1 by an
independent statistician who is not involved with trial
participants or data analysis. A unique six-digit study ID
and a study pack with a unique product ID are assigned.
The study ID identifies the randomised woman and the
product ID identifies a pack of five bottles of either active
or control capsules, prepackaged corresponding to the
randomisation schedule.
Blinding
Participants and their family, care providers, data collectors, outcome assessors, research personnel and data
6

analysts will all be blinded to randomisation group. The
intervention and control capsules are identical in shape,
size, colour, packaging and labelling and uniquely identified only by the product ID. In the DOMInO trial, we
identified that more women in the intervention group
correctly guessed their group allocation. We therefore
added a small amount of tuna oil (5%) to the control
capsules to enhance blinding of study participants. The
randomisation code for an individual participant may be
unblinded in an emergency if the site investigator decides
a participant cannot be adequately treated without
knowing their study treatment allocation. The principal
investigator will be notified and must contact the Data
Management and Analysis Centre, where the randomisation list is securely stored. The time, date, study ID of
the participant and reason for unblinding must be documented and events leading to the emergency unblinding
will be recorded.
Data collection and trial management
A purpose-built web-based clinical trial management
information system (CTMS) with password protection and
defined user-level access is used to facilitate trial management. A record of all women approached, screened for
eligibility and consented is recorded in real time in the
CTMS. Once consented and randomised, the CTMS automatically calculates study milestones for each participant.
This information is readily available for clinical trial staff
to enable scheduling of appointments and sample collection. Data entered by individual study centres is routinely
scrutinised by the Coordinating Centre to monitor
protocol adherence and study progress. Summary reports
including screening data, enrolment, appointment attendance, sample collection, SAEs and study completion
are generated from the CTMS and reviewed at monthly
trial steering committee meetings. Site monitoring visits
to ensure compliance with good clinical practice and the
study protocol are conducted at site start-up and then
6 monthly or as required to ensure the integrity of the
trial.
Data are collected by trained clinical trial staff at each
participating centre onto carbon copy paper CRFs.
Carbon copies of the completed CRF remain on site at
participating centres with original copies being mailed to
the Data Management and Analysis Centre at the University of Adelaide for data management including data entry
and data cleaning. Data validity checks are completed
by data entry personnel and data queries posted to the
CTMS for resolution by participating centres. Data
queries generated by statisticians during regular blinded
reviews of data quality and batch checks are also managed
through the CTMS. Electronic data are stored on secure
servers at the Data Management and Analysis Centre and
released only to persons authorised to receive those data.
Following study completion, copies of study documents
are retained at each study site or in archives. Documents
held at the Coordinating Centre will be retained for at
least 30 years after study completion in line with the
Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360
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non-adherence are expected in the ORIP trial. Inclusion
of women with multiple pregnancies in the ORIP trial is
expected to result in a small increase in the incidence
of EPTB in both treatment groups, since EPTB is more
common in multiple pregnancies. To demonstrate an
absolute reduction in the incidence of EPTB of 1.16%
(from 2.45% to 1.29%) with 85% power and overall
two-sided alpha=0.05 (alpha=0.049 at the final analysis), a sample size of 2631 per group (ie, 5262 total) is
required. Allowing for a loss to follow-up of 5%, a total
of 5540 women is required to ensure adequate power
for the primary outcome. Since EPTB is a mother level
outcome, the sample size calculations define the number
of mothers that should be recruited and no adjustment
for clustering due to multiple pregnancies is required for
this outcome.

Open Access

Statistical methods
All participants will be analysed according to the group
to which they were randomised (intention-to-treat principle) for the primary analysis. The primary outcome
of EPTB will be compared between intervention and
control groups using a log binomial regression model.
Adjustment will be made for the stratification variables
centre and supplements, and results will be presented
as a RR with CI and two-sided p value. Statistical significance will be assessed at an alpha of 0.049 to account
for the prespecified interim analysis (see below) using
the O'Brien-Fleming approach. Key secondary and other
outcomes will be compared between treatment groups
using log binomial regression models for binary outcomes
and linear regression models for continuous outcomes
with no adjustment for multiple comparisons. Clustering
due to multiple pregnancies and repeat participation in
the trial will be taken into account where applicable using
generalised estimating equations. Secondary analyses will
be performed for the primary outcome and related key
secondary and other outcomes to test for evidence of
effect modification by pregnancy status (single vs multiple
pregnancy), history of preterm birth and baseline DHA.
Missing data will be addressed using multiple imputation
under a missing at random assumption. Sensitivity analyses will be performed using the original unimputed data.
A secondary per-protocol analysis will be performed for
the primary outcome including only women who were
compliant with the protocol. Two separate definitions of
compliance will be used. First, women will be considered
compliant if they returned their remaining capsules at the
end of the trial and consumed at least 75% of the number
of capsules expected to be consumed. Second, women
will be considered compliant if they had the 28-week telephone contact and reported they had missed less than
7 capsules in the last week out of the recommended 21
capsules.
All analyses will follow a prespecified statistical analysis
plan. There is a single planned interim analysis of the
primary outcome to be performed after data collection
is complete for the first 50% of the target number of
randomised participants.
Data monitoring
An independent Data Monitoring Committee (DMC)
has been set up to review the progress of the trial and
provide feedback to the Trial Steering Committee.
The DMC reviews general study progress (recruitment,
compliance, loss to follow-up), the EPTB event rate and
key secondary/safety outcomes. The committee meets
annually or as required and consists of a neonatologist,
obstetrician and statistician with clinical trials expertise.
Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360

The DMC will be responsible for reviewing the results of
the interim analysis.
An independent (blinded) SAE Committee has been
established to review SAEs. There are no SAEs which
would be anticipated as a unique consequence of participation in the trial; however, all deaths, admissions to an
intensive care unit of mothers or of infants born after 34
completed weeks’ gestation and major congenital abnormalities are to be reported. The SAE Committee includes
experts in obstetrics, neonatology, pathology and
midwifery who are not involved in the trial. The primary
role of the SAE Committee is to review all SAEs and determine whether there is any likelihood that involvement in
the trial could have contributed to the event. Determinations of causality will be made from medical records
retrieved for this purpose. This committee meets quarterly or as required.

Ethics and dissemination
Research ethics approval
This protocol and the informed consent and participant
information document have been approved by the Human
Research Ethics Committee (HREC) of each study site.
Women’s and Children’s Health Network HREC (Coordinating HREC & Women’s and Children’s Hospital,
Adelaide; Southern Adelaide Clinical HREC, Adelaide,
South Australia); Mercy Health HREC (Werribee Mercy
Hospital, Werribee, Victoria); Mater Mothers’ Hospital,
Brisbane, Queensland; University of Notradame, Joondalup Health Campus, Joondalup, Western Australia. Any
subsequent modifications will be reviewed and approved
by the HREC and governance of each study site. The
study will be conducted in compliance with the current
approved version of the protocol. Any change to the
protocol document or informed consent form that affects
the scientific intent, study design, patient safety or may
affect a participant’s willingness to continue participation in the study will be considered a major amendment.
All such amendments will be submitted to the HREC for
approval. Any other changes to the protocol (such as
administrative changes to dates and study personnel) will
be considered minor amendments and will be notified to
the HREC as appropriate. Study findings will be disseminated via peer-reviewed publication, conference presentations, informing participants with a lay summary and
the wider community through social media.
Confidentiality
Participant confidentiality is strictly held in trust by
the participating investigators, research staff and their
agents. This confidentiality is extended to cover testing
of biological samples in addition to the clinical information relating to participants. The study protocol, documentation, data and all other information generated will
be held in strict confidence. No information concerning
the study or the data will be released to any unauthorised third party, without prior written approval of the
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data retention schedules for research involving minors.22
At the completion of this time, documentation will be
destroyed using confidential document disposal. Electronic data will be stored indefinitely on secure servers
with access only granted to authorised study personnel.

Open Access

Dissemination plan
Study findings will be submitted for peer-reviewed publication and for presentation at appropriate local and
international conferences. In addition, study findings
will be disseminated to participants through a one-page
lay summary. Results will be made available to the wider
community through social media avenues and the South
Australian Health & Medical Research Institute website.
Trial status
This enrolment phase of this trial completed on 27 April
2017 with successful attainment of sample size (n=5544).
Completion of study follow-up appointments and collection of labour and birth data from participant medical
records will be completed by December 2017.
Author affiliations
1
Healthy Mothers, Babies and Children, South Australian Health and Medical
Research Institute, Adelaide, Australia
2
School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, South
Australia, Australia
3
Department of Paediatrics, School of Medicine, The University of Adelaide,
Adelaide, Australia
4
FOOD plus Research Centre, The University of Adelaide, Australia
5
Department of Neonatal Services, Women’s and Children’s Health Network,
Adelaide, Australia
6
School of Public Health, The University of Adelaide, Adelaide, Australia
7
Institute for Health Research, University of Notre Dame Australia, Fremantle,
Australia
Acknowledgements We thank the research and clinical teams at all participating
study centres.
Contributors MM, JQ, RG, AM and SJZ conceived and designed the study with
KB contributing to ongoing study implementation and management. LY provided
statistical expertise. SJZ and KB wrote the first draft of the manuscript. All authors
contributed to refinement of the study protocol and approved the final manuscript.
Funding This work was supported by the National Health and Medical Research
Council (NHMRC) of Australia, grant number 1050468. The study product is donated
by Efamol Ltd/Wassen Intl Ltd. An NHMRC Fellowship supports RG (Senior Principal
Research Fellow 1046207) and MM (Principal Research Fellow 1061704) and LY
(Early Career Research Fellow 1052388). The funding bodies had no role in the
design of this study and will not have any role during the conduct of the study, data
collection, study management, analyses and interpretation of the data or in the
writing, review or approval publications. The contents of the published material are
solely the responsibility of the authors and do not reflect the views of the NHMRC.
Competing interests The authors declare: financial support for the submitted
work from the National Health and Medical Research Council (NHMRC) Australia
(Project Grant 1050468). RG serves on a scientific advisory board for Fonterra; MM
serves on scientific advisory boards for Nestle and Fonterra. Associated Honoraria
for RG and MM are paid to their institutions to support conference travel and
continuing education for postgraduate students and early career researchers. The
authors declare that they have no competing interests.

8

Patient consent Detail has been removed from this case description/these case
descriptions to ensure anonymity. The editors and reviewers have seen the detailed
information available and are satisfied that the information backs up the case the
authors are making.
Ethics approval Human Research Ethics Committee (HREC) of each study site.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Once the primary trial is published, ORIP data will
be available for data sharing. Please send requests to Maria Makrides (maria.
makrides@sahmri.com) and Karen Best (karen.best@adelaide.edu.au).
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the
article) 2017. All rights reserved. No commercial use is permitted unless otherwise
expressly granted.

References

1. Thornton S. Preterm Birth: Causes, Consequences and Prevention.
The Obstetrician & Gynaecologist 2008;10:280–80.
2. Lumley J. Defining the problem: the epidemiology of preterm birth.
BJOG 2003;110 (Suppl 20):3–7.
3. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2004.
Natl Vital Stat Rep 2006;55:1–101.
4. Pretorius C, Jagatt A, Lamont RF. The relationship between
periodontal disease, bacterial vaginosis, and preterm birth. J Perinat
Med 2007;35:93–9.
5. Gravett MG. Causes of preterm delivery. Semin Perinatol
1984;8:246–57.
6. Karim SM. The role of prostaglandins in human parturition. Proc R
Soc Med 1971;64:10–12.
7. Brazle AE, Johnson BJ, Webel SK, et al. Omega-3 fatty acids in
the gravid pig uterus as affected by maternal supplementation with
omega-3 fatty acids. J Anim Sci 2009;87:994–1002.
8. Prescott SL. Early-life environmental determinants of allergic
diseases and the wider pandemic of inflammatory noncommunicable
diseases. J Allergy Clin Immunol 2013;131:23–30.
9. Meyer BJ, Mann NJ, Lewis JL, et al. Dietary intakes and food
sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids
2003;38:391–8.
10. Oken E, Kleinman KP, Berland WE, et al. Decline in fish consumption
among pregnant women after a national mercury advisory. Obstet
Gynecol 2003;102:346–51.
11. Escamilla-Nuñez MC, Barraza-Villarreal A, Hernández-Cadena L,
et al. Omega-3 fatty acid supplementation during pregnancy and
respiratory symptoms in children. Chest 2014;146:373–82.
12. Bulstra-Ramakers MT, Huisjes HJ, Visser GH. The effects of 3g
eicosapentaenoic acid daily on recurrence of intrauterine growth
retardation and pregnancy induced hypertension. Br J Obstet
Gynaecol 1995;102:123–6.
13. Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of
fish oil supplementation in high risk pregnancies. Fish Oil Trials In
Pregnancy (FOTIP) Team. BJOG 2000;107:382–95.
14. Horvath A, Koletzko B, Szajewska H. Effect of supplementation of
women in high-risk pregnancies with long-chain polyunsaturated
fatty acids on pregnancy outcomes and growth measures at
birth: a meta-analysis of randomized controlled trials. Br J Nutr
2007;98:253–9.
15. Szajewska H, Horvath A, Koletzko B. Effect of n-3 long-chain
polyunsaturated fatty acid supplementation of women with low-risk
pregnancies on pregnancy outcomes and growth measures at birth:
a meta-analysis of randomized controlled trials. Am J Clin Nutr
2006;83:1337–44.
16. Makrides M, Gibson RA, McPhee AJ, et al. Effect of DHA
supplementation during pregnancy on maternal depression and
neurodevelopment of young children: a randomized controlled trial.
JAMA 2010;304:1675–83.
17. Carlson SE, Colombo J, Gajewski BJ, et al. DHA supplementation
and pregnancy outcomes.
Am J Clin Nutr 2013;97:808–15.
18. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin
precursor, supplementation for pregnancy uncomplicated by pre-

Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360

BMJ Open: first published as 10.1136/bmjopen-2017-018360 on 24 September 2017. Downloaded from http://bmjopen.bmj.com/ on 22 April 2018 by guest. Protected by copyright.

Coordinating Centre. The Coordinating Centre and regulatory authorities may inspect all documents and records
required to be maintained by the investigator, including
but not limited to, medical records and pharmacy records
for the infants in this study subject to individuals having
obtained approval/clearance through State/National
Governments and HREC as required by local laws. The
study site will permit access to such records. Clinical information will not be released without written permission of
the parent/guardian, except as necessary for monitoring
by HREC or regulatory agencies.

Open Access

Zhou SJ, et al. BMJ Open 2017;7:e018360. doi:10.1136/bmjopen-2017-018360

21. Moher D, Schulz KF, Altman DG. CONSORT. The CONSORT
statement: revised recommendations for improving the quality of
reports of parallel group randomized trials. BMC Med Res Methodol
2001;1:2.
22. Governance R. Site Specific Assessment: Submission Guidelines:
Women’s and Children’s Health Network RG, ed. Site Specific
Assessment: Submission Guidelines. Adelaide: Women’s and
Children’s Health Network, 2016.

9

BMJ Open: first published as 10.1136/bmjopen-2017-018360 on 24 September 2017. Downloaded from http://bmjopen.bmj.com/ on 22 April 2018 by guest. Protected by copyright.

eclampsia or intrauterine growth restriction. Cochrane Database Syst
Rev 2006:CD003402.
19. Philippa Middleton JG, Shepherd E, Makrides M. Omega-3
supplementation during pregnancy: an updated Cochrane review. J
Paediatr Child Health 2017;53:68–9.
20. Australian and New Zealand Neonatal Network A. Australian and
New Zealand Network Data Dictionary, Definitions for audit Australian
and New Zealand Network Data Dictionary. Australia, 2013.

